Salomeh Keyhani1, Eric M Cheng2, Katherine Hoggatt1, Peter C Austin3, Erin Madden4, Paul L Hebert5,6, Ethan A Halm7, Ayman Naseri8,9, Jason Johanning10, Ann Abraham4, Dawn M Bravata11,12,13. 1. Department of Medicine, UCSF Division of General Internal Medicine, San Francisco Veterans Affairs Medical Center, CA (S.K., K.H.). 2. Department of Neurology, University of California Los Angeles, VA Greater Los Angeles Healthcare System (E.M.C.). 3. Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada (P.C.A.). 4. Northern California Institute for Research and Education, San Francisco (E.M., A.A.). 5. University of Washington School of Public Health, Seattle (P.L.H.). 6. VA Puget Sound Seattle, WA (P.L.H.). 7. Division of General Internal Medicine, University of Texas Southwestern Medical Center, Dallas (E.A.H.). 8. Department of Ophthalmology, University of California San Francisco (A.N.). 9. San Francisco Veterans Affairs Medical Center, CA (A.N.). 10. Department of Surgery, University of Nebraska and Omaha VA Medical Center (J.J.). 11. Richard L. Roudebush VA Medical Center, Indianapolis, Indiana (D.M.B.). 12. Departments of Medicine (D.M.B.), Indiana University School of Medicine, Indianapolis. 13. Neurology (D.M.B.), Indiana University School of Medicine, Indianapolis.
Abstract
BACKGROUND: No completed trials have compared carotid artery stenting (CAS) to medical therapy (MT). We examined the effectiveness of CAS compared with MT in patients with asymptomatic carotid stenosis. METHODS: We conducted a retrospective cohort study of 219 979 Veterans ≥65 years who received carotid imaging for asymptomatic carotid stenosis between 2005 and 2009 in the US Veterans Health Administration. We constructed a sample of patients who received MT (n=2509) and comparable patients who received CAS (n=551) and followed them for 5 years. Using target trial methodology, we computed weighted Kaplan-Meier curves and estimated the risk of fatal and nonfatal stroke in each group over 5 years of follow-up. We also estimated the cumulative incidence functions for fatal and nonfatal stroke accounting for nonstroke deaths as competing risks. RESULTS: Five hundred fifty-one patients received CAS, and 2509 patients received MT. The observed rate of stroke or death (perioperative complications) within 30 days in the CAS arm was 2.2%. Using the target trial methodology, the 5-year risk of fatal and nonfatal stroke was similar among patients assigned to CAS (6.9%) compared with patients assigned to MT (7.1%; risk difference, -0.1% [95% CI, -2.6% to 2.7%]). In an analysis that incorporated the competing risk of death, the risk difference between the two arms remained nonsignificant (risk difference, -1.5% [95% CI, -3.0% to 0.3%]). CONCLUSIONS: In this sample of older male adults, we found no difference between MT and CAS in the treatment of asymptomatic carotid stenosis. Future studies in other settings are needed to confirm these findings.
BACKGROUND: No completed trials have compared carotid artery stenting (CAS) to medical therapy (MT). We examined the effectiveness of CAS compared with MT in patients with asymptomatic carotid stenosis. METHODS: We conducted a retrospective cohort study of 219 979 Veterans ≥65 years who received carotid imaging for asymptomatic carotid stenosis between 2005 and 2009 in the US Veterans Health Administration. We constructed a sample of patients who received MT (n=2509) and comparable patients who received CAS (n=551) and followed them for 5 years. Using target trial methodology, we computed weighted Kaplan-Meier curves and estimated the risk of fatal and nonfatal stroke in each group over 5 years of follow-up. We also estimated the cumulative incidence functions for fatal and nonfatal stroke accounting for nonstroke deaths as competing risks. RESULTS: Five hundred fifty-one patients received CAS, and 2509 patients received MT. The observed rate of stroke or death (perioperative complications) within 30 days in the CAS arm was 2.2%. Using the target trial methodology, the 5-year risk of fatal and nonfatal stroke was similar among patients assigned to CAS (6.9%) compared with patients assigned to MT (7.1%; risk difference, -0.1% [95% CI, -2.6% to 2.7%]). In an analysis that incorporated the competing risk of death, the risk difference between the two arms remained nonsignificant (risk difference, -1.5% [95% CI, -3.0% to 0.3%]). CONCLUSIONS: In this sample of older male adults, we found no difference between MT and CAS in the treatment of asymptomatic carotid stenosis. Future studies in other settings are needed to confirm these findings.
Authors: S Chaturvedi; A Bruno; T Feasby; R Holloway; O Benavente; S N Cohen; R Cote; D Hess; J Saver; J D Spence; B Stern; J Wilterdink Journal: Neurology Date: 2005-09-27 Impact factor: 9.910
Authors: Miguel A Hernán; Brian C Sauer; Sonia Hernández-Díaz; Robert Platt; Ian Shrier Journal: J Clin Epidemiol Date: 2016-05-27 Impact factor: 6.437
Authors: Virginia J Howard; James F Meschia; Brajesh K Lal; Tanya N Turan; Gary S Roubin; Robert D Brown; Jenifer H Voeks; Kevin M Barrett; Bart M Demaerschalk; John Huston; Ronald M Lazar; Wesley S Moore; Virginia G Wadley; Seemant Chaturvedi; Claudia S Moy; Marc Chimowitz; George Howard; Thomas G Brott Journal: Int J Stroke Date: 2017-05-02 Impact factor: 5.266
Authors: Patric Liang; Yoel Solomon; Nicholas J Swerdlow; Chun Li; Rens R B Varkevisser; Livia E V M de Guerre; Marc L Schermerhorn Journal: J Vasc Surg Date: 2020-02-13 Impact factor: 4.268
Authors: Louise Emilsson; Xabier García-Albéniz; Roger W Logan; Ellen C Caniglia; Mette Kalager; Miguel A Hernán Journal: JAMA Oncol Date: 2018-01-01 Impact factor: 31.777